Investigational drug · Phase 2
OKI-179
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for RAS Mutation, NRAS Gene Mutation, Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "OKI-179"
First trial start
2022
May 11, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OKI-179", any sponsor or status.
Conditions studied
As listed on its trial records.
- RAS Mutation
- NRAS Gene Mutation
- Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "OKI-179" as an intervention, largest first.
OnKure, Inc.Industry
NCT05340621 · 36 participants · Start May 11, 2022 · Primary completion Jan 29, 2025
Drug: OKI-179 + binimetinib · For: RAS Mutation; NRAS Gene Mutation; Melanoma
Sites: Phoenix, Arizona; San Francisco, California; Gainesville, Florida · 12 sites in all
OnKure, Inc.Industry
NCT03931681 · 34 participants · Start May 8, 2019 · Primary completion Nov 27, 2021
Drug: OKI-179 · For: Advanced Solid Tumors
Sites: Aurora, Colorado
Newest research
PubMed records naming it or its code names, newest first.
- Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Smoots SG, Schreiber AR, Jackson MM, et al. · Breast Cancer Res 2024
- First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
Schreiber AR, Kagihara JA, Corr BR, et al. · Cancers (Basel) 2023
- Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Holay N, Somma A, Duchow M, et al. · Front Immunol 2023
- Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond JR, Pitts TM, Ungermannova D, et al. · Mol Cancer Ther 2022
- Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.
Wu L, Ye K, Jiang S, et al. · Mar Drugs 2021
- Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Wang X, Waschke BC, Woolaver RA, et al. · Cancer Immunol Res 2019
Also in development for RAS Mutation
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
- ERAS-0015Phase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
- vopimetostatPhase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.